Risk Factor (RF)

HR

95% CI

Comorbidities, ≥2

1.19

1.04 - 1.36

ECOG, ≥2

1.40

0.99 - 2.14

Signet Ring Cells, >50%

1.37

1.07 - 1.72

Her2 Treated with Trastuzumab

0.71

0.50 - 0.96

Metastatic Sites, ≥2

1.26

1.08 - 1.63

CEA, ≥20

1.32

1.23 - 1.69

Bone Metastases

1.99

1.37 - 2.89

Ascitis

1.67

1.26 - 2.21